Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(10%)
Results Posted
113%(9 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph phase_3
2
20%
Ph not_applicable
5
50%
Ph phase_4
2
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
5(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (10.0%)
Phase 32 (20.0%)
Phase 42 (20.0%)
N/A5 (50.0%)

Trials by Status

terminated110%
active_not_recruiting110%
completed880%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
10